Synaptogenix Inc. (NASDAQ: SNPX) stock fell -5.08% on Monday to $0.30 against a previous-day closing price of $0.31. With 2.53 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.94 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3605 whereas the lowest price it dropped to was $0.2900. The 52-week range on SNPX shows that it touched its highest point at $8.02 and its lowest point at $0.30 during that stretch. Beta for the stock currently stands at 1.72.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNPX was down-trending over the past week, with a drop of -12.83%, but this was down by -49.19% over a month. Three-month performance dropped to -67.14% while six-month performance fell -64.17%. The stock lost -96.30% in the past year, while it has lost -74.22% so far this year.
Float and Shares Shorts:
At present, 10.16 million SNPX shares are outstanding with a float of 9.46 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.36 million, which was 3.53% higher than short shares on Jul 30, 2023. In addition to Dr. Alan J. Tuchman M.D., MBA(FAAN) as the firm’s CEO & Director, Dr. Daniel L. Alkon M.D. serves as its Pres, Chief Scientific Officer & Director.
Institutional Ownership:
Through their ownership of 3.69% of SNPX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, SNPX reported revenue of $0.00 and operating income of -$3.80M. The EBITDA in the recently reported quarter was -$3.80M and diluted EPS was -$0.54.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SNPX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SNPX analysts setting a high price target of $14.00 and a low target of $14.00, the average target price over the next 12 months is $14.00. Based on these targets, SNPX could surge 4566.67% to reach the target high and rise by 4566.67% to reach the target low. Reaching the average price target will result in a growth of 4566.67% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded SNPX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 5 over the past year. The total number of shares bought during that period was 0 while 115,762 shares were sold.
